Effects of Sedation Doses of Propofol and Midazolam on Levels of NGAL, Cystatin-C, KIM-1 in Rats

INTRODUCTION: Limited data are available regarding the impact of their sedation doses midazolam and propofol on early biomarkers of acute kidney injury (AKI). This study aimed to investigate the effects of sedation doses propofol and midazolam on early biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL), cystatin C (CyC) and kidney injury molecule 1 (KIM-1) of AKI.
METHODS: A total of 24 Wistar albino rats were separated into three groups (n = 8 per group): a control group (intraperitoneal injection [IP] saline injection once daily for 7 days), a propofol group (IP injection of 2.5 mg/kg propofol once daily for 7 days), and a midazolam group (IP injection of 5 mg/kg midazolam once daily for 7 days). For each group, urinalysis (for urea, creatinine, total protein, NGAL, CyC, and KIM-1) was performed on Day 0 and Day 7; serum analysis (for urea, creatinine, total protein, albumin globulin, ALT, AST, NGAL, CyC, and KIM-1) was performed on day 7.
RESULTS: No significant difference was noted between control, propofol and midazolam groups in terms of Day 7 serum KIM-1, CyC, and NGAL levels and Day 0 and Day 7 urinalysis findings (KIM-1, CyC, NGAL, urea, and creatinine levels).
DISCUSSION AND CONCLUSION: The findings revealed a similar safety profile for seven-day propofol and midazolam administration in rats in terms of the traditional (creatinine, urea) and early biomarkers (NGAL, CyC, KIM-1) of AKI